Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 4, 2002, Pages 329-335

  Pavillard, Valérie ^a,b   Agostini, Cécile ^a,b   Richard, Sophie ^a,b   Charasson, Virginie ^a,b   Montaudon, Danièle ^a,b   Robert, Jacques ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

Camptothecin; Colon cancer; Drug activation; Irinotecan; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; DNA TOPOISOMERASE; DRUG METABOLITE; IRINOTECAN; MESSENGER RNA;

ARTICLE; CATALYSIS; CELL STRAIN HT29; COLORECTAL TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CATALYSIS; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; HT29 CELLS; HUMANS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036206897     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0416-0     Document Type: Article

References (30)

1. Phosphoglucomutase activity (renal, hepatic, and blood) in rats during experimental poisoning with uranyl nitrate
2. Are there several colorectal cancers? Epidemiological data
3. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
4. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
5. Purification of rat brain succinate-semialdehyde dehydrogenase and study of its inhibition by branched chain fatty acids
6. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
7. Purification and properties of phosphoglucomutase from Fleichermann's yeast
8. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
9. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
10. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: Application to clinical pharmacokinetic studies
11. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts
12. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
13. Eukaryotic DNA topoisomerases I
14. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis by human liver microsomes
15. Characterisation of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
16. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
17. CPT-11 in human colon cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
18. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug-resistant cells
19. Intracellular roles of SN-38, a metabolite of the camptothecin derivative of CPT-11, in the antitumor effect of CPT-11
20. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
21. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors
22. In vitro and in vivo effects of clinically important camptothecin analogues on multi-drug resistant cells
23. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
24. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
25. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
26. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
27. Analysis of topoisomerase I/DNA complexes in patients administered topotecan
28. Biological characterization and oncogene expression in human colorectal carcinoma cell lines
29. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
30. Cross-resistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations